Kura Oncology Announces 2024 Annual Meeting of Stockholders on June 5

TL;DR

<b>Kura Oncology is holding its 2024 Annual Meeting of Stockholders on June 5, 2024, to elect directors and ratify auditor selection.</b>

AI Summary

Kura Oncology, Inc. (KURA) filed a Proxy Statement (DEF 14A) with the SEC on April 12, 2024. Kura Oncology, Inc. will hold its 2024 Annual Meeting of Stockholders on June 5, 2024, at 8:30 a.m. Pacific Time. The meeting's agenda includes the election of two Class I director nominees for three-year terms. Stockholders will also vote to ratify the selection of the independent registered public accounting firm by the Audit Committee. The filing is a Definitive Proxy Statement (DEF 14A) filed on April 12, 2024. The company is incorporated in Delaware and its fiscal year ends on December 31.

Why It Matters

For investors and stakeholders tracking Kura Oncology, Inc., this filing contains several important signals. This filing provides crucial information for stockholders to make informed voting decisions regarding board composition and financial oversight. The election of directors and ratification of the auditor are key governance activities that impact the company's strategic direction and accountability.

Risk Assessment

Risk Level: low — Kura Oncology, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational risks indicated.

Analyst Insight

Stockholders should review the director nominees and auditor ratification proposals to exercise their voting rights effectively.

Key Numbers

• June 5, 2024 — Annual Meeting Date (2024 Annual Meeting of Stockholders)
• 8:30 a.m. Pacific Time — Meeting Time (2024 Annual Meeting of Stockholders)
• 2 — Director Nominees (To elect two nominees for Class I director)
• 3-year terms — Director Term Length (Until the 2027 Annual Meeting of Stockholders)

Key Players & Entities

• Kura Oncology, Inc. (company) — Registrant Name
• June 5, 2024 (date) — Annual Meeting Date
• Class I director (director) — Nominees for election
• Audit Committee (board_committee) — Selection of auditor
• DEF 14A (filing_type) — Filing Type
• 2024-04-12 (date) — Filing Date

FAQ

Risk Factors

• Proxy Statement Filing [low — regulatory]: The filing is a routine DEF 14A proxy statement, indicating compliance with SEC disclosure requirements for annual meetings.

Industry Context

Kura Oncology operates in the pharmaceutical preparations industry, focusing on developing and commercializing targeted cancer therapies.

Regulatory Implications

The filing adheres to SEC regulations for proxy solicitations, specifically Schedule 14A, ensuring transparency in corporate governance.

What Investors Should Do

1. Review the profiles and qualifications of the two Class I director nominees.
2. Evaluate the rationale for ratifying the Audit Committee's selection of the independent registered public accounting firm.
3. Vote on the director nominees and auditor ratification before the Annual Meeting on June 5, 2024.

Key Dates

• 2024-06-05: Annual Meeting of Stockholders — Key date for voting on director nominees and auditor ratification.
• 2024-04-12: Filing Date — Date the Definitive Proxy Statement was filed with the SEC.

Year-Over-Year Comparison

This is the initial filing for the 2024 Annual Meeting of Stockholders, providing details on upcoming votes.

Filing Documents

• kura-20240412.htm (DEF 14A) — 1594KB
• img1234521_0.jpg (GRAPHIC) — 2KB
• img1234521_1.jpg (GRAPHIC) — 312KB
• img1234521_2.jpg (GRAPHIC) — 242KB
• img1234521_3.jpg (GRAPHIC) — 3KB
• img1234521_4.jpg (GRAPHIC) — 1358KB
• img1234521_5.jpg (GRAPHIC) — 167KB
• 0000950170-24-044066.txt (&nbsp;) — 7111KB
• kura-20240412.xsd (EX-101.SCH) — 68KB
• kura-20240412_htm.xml (XML) — 141KB

Executive Compensation

Executive Compensation 35

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 65 Non-Employee Director Compensation 68 Certain Relationships and Related Party Transactions 70 Householding of Proxy Materials 73 Other Matters 73 Appendix A: Amended and Restated 2014 Equity Incentive Plan A-1 KURA ONCOLOGY, INC. PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS To be held on June 5, 2024 QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Why did I receive a notice regarding the availability of proxy materials on the internet? We have sent you a Notice of Internet Availability of Proxy Materials (the "Notice") because the Board of Directors (sometimes referred to as the "Board") of Kura Oncology, Inc. (sometimes referred to as "we," "us," the "Company" or "Kura") is soliciting your proxy to vote at the 2024 Annual Meeting of Stockholders, including at any adjournments or postponements of the meeting (the "Annual Meeting"). Pursuant to rules adopted by the Securities and Exchange Commission (the "SEC"), we have elected to provide access to our proxy materials over the internet. Accordingly, we have sent a Notice to our stockholders of record. All stockholders will have the ability to access the proxy materials on the website referred to in the Notice or request to receive a printed set of the proxy materials. Instructions on how to access the proxy materials over the internet or to request a printed copy may be found in the Notice. We intend to mail the Notice on or about April 18, 2024 to all stockholders of record entitled to vote at the Annual Meeting. Will I receive any other proxy materials by mail? We may send you a proxy card, along with a second notice, on or after April 29, 2024. What is the format of the Annual Meeting? The Annual Meeting will be held through a live webcast at www.proxydocs.com/KURA. You will not be able to attend the meeting in person. We may resume holding in-person annual meetings in the fut

View Full Filing

View this DEF 14A filing on SEC EDGAR